{"nctId":"NCT02558374","briefTitle":"Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2015-09"},"conditions":["Open-angle Glaucoma","Ocular Hypertension"],"count":708,"armGroups":[{"label":"AR-13324 Ophthalmic Solution 0.02% & placebo","type":"EXPERIMENTAL","interventionNames":["Drug: AR-13324 Ophthalmic Solution 0.02%","Other: Placebo"]},{"label":"Timolol Maleate Ophthalmic Solution 0.5% BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Timolol Maleate Ophthalmic Solution 0.5% BID"]}],"interventions":[{"name":"AR-13324 Ophthalmic Solution 0.02%","otherNames":["Netarsudil"]},{"name":"Timolol Maleate Ophthalmic Solution 0.5% BID","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 18 years of age or older\n2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes\n3. Post-washout intraocular pressure \\>20mmHg and \\<30mmHg in 1 or both eyes at 2 qualification visits\n4. Corrected visual acuity equivalent to 20/200\n5. Able to give informed consent and follow study instructions\n\nExclusion Criteria:\n\n1. Clinically significant ocular disease\n2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles\n3. Unmedicated intraocular pressure ≥30mmHg\n4. Use of more than 2 ocular hypotensive medications within 30 days of screening\n5. Known hypersensitivity to any component of the formulation\n6. Previous glaucoma surgery or refractive surgery\n7. Ocular trauma within 6 months prior to screening\n8. Any ocular surgery or non-refractive laser treatment within 3 months prior to screening\n9. Recent or current ocular infection or inflammation in either eye\n10. Used ocular medication in either eye of any kind within 30 days of screening\n11. Mean central corneal thickness \\>620µm at screening\n12. Any abnormality preventing reliable applanation tonometry of either eye\n13. Clinically significant abnormalities in lab tests at screening\n14. Known hypersensitivity or contraindication to beta-adrenoceptor antagonists\n15. Clinically significant systemic disease\n16. Participation in any investigational study within 60 days prior to screening\n17. Used any systemic medication that could have a substantial effect in intraocular pressure within 30 days prior to screening\n18. Women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"IOP (Intraocular Pressure)","description":"The primary efficacy outcome is mean IOP","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.93","spread":"2.441"},{"groupId":"OG001","value":"23.89","spread":"2.318"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.67","spread":"2.826"},{"groupId":"OG001","value":"22.77","spread":"2.565"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.17","spread":"2.857"},{"groupId":"OG001","value":"22.04","spread":"2.708"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.20","spread":"3.833"},{"groupId":"OG001","value":"18.60","spread":"3.396"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.93","spread":"3.678"},{"groupId":"OG001","value":"17.80","spread":"3.237"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.76","spread":"3.527"},{"groupId":"OG001","value":"17.85","spread":"3.102"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.45","spread":"3.929"},{"groupId":"OG001","value":"18.52","spread":"3.316"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.12","spread":"3.560"},{"groupId":"OG001","value":"17.89","spread":"3.157"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.89","spread":"3.438"},{"groupId":"OG001","value":"17.88","spread":"3.356"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.24","spread":"3.889"},{"groupId":"OG001","value":"18.35","spread":"3.196"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.30","spread":"3.637"},{"groupId":"OG001","value":"17.60","spread":"3.173"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.02","spread":"3.644"},{"groupId":"OG001","value":"17.66","spread":"3.080"}]}]}]},{"type":"SECONDARY","title":"Extent of Exposure","description":"Exposure to study medication in days for all treatment groups","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147.4","spread":"54.47"},{"groupId":"OG001","value":"167.7","spread":"36.40"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":351},"commonTop":["Conjunctival Hyperaemia","Instillation Site Pain","Cornea Verticillata","Conjunctival Haemorrhage","Vital Dye Staining Cornea Present"]}}}